GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VGI Health Technology Ltd (XNEC:VTL) » Definitions » Cash-to-Debt

VGI Health Technology (XNEC:VTL) Cash-to-Debt : 0.00 (As of . 20)


View and export this data going back to 2021. Start your Free Trial

What is VGI Health Technology Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. VGI Health Technology's cash to debt ratio for the quarter that ended in . 20 was 0.00.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, VGI Health Technology couldn't pay off its debt using the cash in hand for the quarter that ended in . 20.

The historical rank and industry rank for VGI Health Technology's Cash-to-Debt or its related term are showing as below:

XNEC:VTL's Cash-to-Debt is not ranked *
in the Biotechnology industry.
Industry Median: 6.505
* Ranked among companies with meaningful Cash-to-Debt only.

VGI Health Technology Cash-to-Debt Historical Data

The historical data trend for VGI Health Technology's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

VGI Health Technology Cash-to-Debt Chart

VGI Health Technology Annual Data
Trend
Cash-to-Debt

VGI Health Technology Semi-Annual Data
Cash-to-Debt

Competitive Comparison of VGI Health Technology's Cash-to-Debt

For the Biotechnology subindustry, VGI Health Technology's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VGI Health Technology's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VGI Health Technology's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where VGI Health Technology's Cash-to-Debt falls into.



VGI Health Technology Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

VGI Health Technology's Cash to Debt Ratio for the fiscal year that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

VGI Health Technology's Cash to Debt Ratio for the quarter that ended in . 20 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


VGI Health Technology  (XNEC:VTL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.


VGI Health Technology Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of VGI Health Technology's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


VGI Health Technology (XNEC:VTL) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
19 Martin Place, Level 45, Suite 03, Sydney, NSW, AUS, 2003
VGI Health Technology Ltd develops and commercializes evidence-based nutraceuticals and pharmaceuticals. It has two evidence-based nutraceutical products ready for commercial launch in the US as well as a therapeutic drug development program. The nE1-Heart targets maintenance of heart health - tocotrienols have a similar mode of action (inhibition of HMCG CoA biosynthesis) as statins, the Gold Standard for treatment of hyperlipidaemia; and nE1-Eliteth that reduces Delayed Onset Muscle Soreness, improves muscle recovery after exercise, exercise endurance and maintenance of peak muscle power.

VGI Health Technology (XNEC:VTL) Headlines

No Headlines